NCT01270789View on ClinicalTrials.gov

LIraglutide and Beta-cell RepAir (LIBRA) Study

PHASE3CompletedINTERVENTIONAL

Enrollment

63

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

May 31, 2014

Conditions

Type 2 Diabetes

Interventions

DRUG

Liraglutide

Liraglutide administered as once daily sc injection

DRUG

placebo

placebo administered as once daily sc injection

Trial Locations (1)

M5G1X5

Mount Sinai Hospital, Toronto

Sponsors

Collaborators (1)

Novo Nordisk A/S

All Listed Sponsors

collaborator

Novo Nordisk A/S

INDUSTRY

lead

Mount Sinai Hospital, Canada

OTHER